Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Phase 1: To evaluate the toxicity profile of escalating doses of CO-1686 and to determine the MTD and RP2D To characterize the PK profile of CO-1686 Phase 2: To evaluate tumor response (ORR + duration of response) to CO-1686 in patients with T790M
Inclusion criteria
- Previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or gefitinib